人乳头瘤病毒疫苗时代高级别宫颈癌前病变的趋势
研究分析田纳西州戴维森县18-39岁女性2008至2013年CIN2+及原位腺癌的发病率趋势,发现18-20岁和21-24岁女性CIN2+发病率下降,25-29岁和30-39岁女性无显著变化。活检标本中至少一种疫苗型HPV基因型患病率从2008年59%降至2013年52%(p=0.003)。
要点
- 18-20岁女性CIN2+发病率从188.9降至58.7/10万,年度变化百分比-24.2(95%CI -41.4,-2.1)。
- 21-24岁女性CIN2+发病率从495.6降至332.4/10万,年度变化百分比-10.2%(95%CI -16.3,-3.4)。
- 25-29岁和30-39岁女性CIN2+发病率无显著变化。
核心结论
- 18-24岁女性CIN2+诊断减少,但年龄更大女性未减少。
- 筛查变化和HPV疫苗接种均可能促成年轻女性CIN2+下降。
研究设计与样本
- 通过服务该人群的实验室病理报告识别田纳西州戴维森县18-39岁女性中宫颈上皮内瘤变2级及以上及原位腺癌(CIN2+)病例。
- 收集活检标本进行HPV基因分型。
- 检查2008年至2013年CIN2+发病率及相关HPV基因型的趋势。
主要发现
- 共识别2031名CIN2+女性。
- 18-20岁女性CIN2+发病率从188.9降至58.7/10万(年度变化百分比=-24.2,95%CI=-41.4,-2.1)。
- 21-24岁女性CIN2+发病率从495.6降至332.4/10万(年度变化百分比=-10.2%,95%CI=-16.3,-3.4)。
- 25-29岁和30-39岁女性CIN2+发病率无显著变化。
- 2031名女性中1319名(65%)的活检标本中,1270名(96%)鉴定出至少一种HPV基因型。
关键数值与推荐
- 18-20岁女性CIN2+发病率年度变化百分比=-24.2(95%CI=-41.4,-2.1)。
- 21-24岁女性CIN2+发病率年度变化百分比=-10.2%(95%CI=-16.3,-3.4)。
- 四种疫苗HPV基因型(6、11、16和18)中至少一种的患病率从2008年59%降至2013年52%(p=0.003)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The 2006 introduction of human papillomavirus vaccine targeted against genotypes 6, 11, 16, and 18 should result in decreased cervical dysplasia in vaccinated women. However, new cervical cancer guidelines to increase screening intervals complicate interpretation of trends. The hypothesis is that cervical dysplasia would decrease only in young vaccine-eligible women, and not older women. METHODS: The authors identified Davidson County, Tennessee, women aged 18-39 years with cervical intraepithelial neoplasia (CIN) grade 2 or greater and adenocarcinoma in situ, denoted as CIN2+, through pathology reports from laboratories serving this population. Biopsy specimens for human papillomavirus genotyping were collected. Trends in CIN2+ rates and associated human papillomavirus genotypes, 2008 through 2013, were examined. RESULTS: The authors identified 2,031 women with CIN2+. Rates of CIN2+ fell from 188.9 to 58.7 per 100,000 women aged 18-20 years (annual percentage change= -24.2, 95% CI= -41.4, -2.1) and from 495.6 to 332.4 per 100,000 women aged 21-24 years (annual percentage change= -10.2%, 95% CI= -16.3, -3.4). There was no significant change in CIN2+ rates for women aged 25-29 or 30-39 years. In biopsy specimens from 1,319 of 2,031 (65%) women, at least one human papillomavirus genotype was identified in 1,270 (96%). The prevalence of at least one of four vaccine human papillomavirus genotypes (6, 11, 16, and 18) declined from 59% in 2008 to 52% in 2013 (p=0.003). CONCLUSIONS: Diagnosis of CIN2+ decreased in women aged 18-24 years, but not in older women. Both changes in screening and human papillomavirus vaccination could have contributed to the decline of CIN2+ in young women.
引用
- Oakley F, Desouki MM, Pemmaraju M, et al. Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era. Am J Prev Med. 2018. PMID: 29778314. doi:10.1016/j.amepre.2018.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。